ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LY4006896

A development code.

Its studies are mostly in Parkinson Disease, led by Eli Lilly.

Furthest: phase 1, since Jan 31, 20251 company-led study, 1 open or runningNext primary completion: Oct 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 1since Jan 31, 2025Jan 31, 2025Oct 2028phase 1 · NCT06809400

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2025First study: phase 1 study in Parkinson DiseaseFirst studyNCT06809400 · 90 planned · United States, Japan
  2. Oct 14, 2026Primary completion moved from 2028-01 to 2028-10Date moved laterphase 1 · +9 months · NCT06809400

Ahead

  1. Oct 2028Primary completion: phase 1 study in Parkinson DiseaseNCT06809400

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06809400Parkinson Disease · United States, Japan1RecruitingOct 202890

How it is read

Names in the registry

  • “LY4006896”, 1 entry

Codes read as this program: LY4006896.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.